NOVO — Maj 2024
-
Kort video: NVIDIA kom onsdag med et imponerende regnskab, hvor de i Q1 har tredoblet salget. NVIDIA's succes smitter af på en masse andre selskaber i sektoren, hvor kursstigninger breder sig som ringe i vandet. En anden vindersektor er fedmesektoren, hvor en af frontløberne, Novo Nordisk, har sat ny ATH. Omtalte selskaber i videoen: NVIDIA, Novo Nordisk, Eli Lilly, Zealand Pharma, Gubra https://proinvestor.com/boards/120587
-
Godmorgen
-
Aktier/tendens: Novo, Mærsk og Zealand Pharma i fokus i ventet rød start https://proinvestor.com/investornyt/1163968/aktier-tendens-novo-maersk-og-zealand-pharma-i-fokus-i-ventet-rod-start
-
Novos Ozempic reducerer risikoen for nyresygdom: Bekræfter hovedkonklusion https://proinvestor.com/investornyt/1164060/novos-ozempic-reducerer-risikoen-for-nyresygdom-bekraefter-hovedkonklusion
-
Novo-konkurrent investerer 36 mia. kr. i øget produktion af fedmemiddel https://proinvestor.com/investornyt/1164226/novo-konkurrent-investerer-36-mia-kr-i-oget-produktion-af-fedmemiddel
-
US FDA panel votes against Novo Nordisk's weekly insulin in type 1 diabetes patients: https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-votes-against-use-novo-nordisks-weekly-insulin-type-1-diabetes-2024-05-24/
-
Transcript: Q&A med CEO Adam Steensberg fra Zealand Pharma https://proinvestor.com/boards/120607
-
Jeg kommenterer FDA afgørelsen her: https://proinvestor.com/boards/120606
-
Novo: FDA-ekspertpanel anbefaler ikke godkendelse af nyt insulin i type 1-diabetes https://proinvestor.com/investornyt/1164754/novo-fda-ekspertpanel-anbefaler-ikke-godkendelse-af-nyt-insulin-i-type-1-diabetes
-
“Bernie Sanders angriber Novo Nordisk, men det virkelige problem er i USA” https://borsen.dk/nyheder/opinion/bernie-sanders-angriber-novo-nordisk-men-det-virkelige-problem-er-i-usa?b_source=borsen&b_medium=row_0&b_campaign=list_9
-
Ozempic kan ifølge nyt studie forebygge kronisk nyresygdom https://finans.dk/erhverv/ECE17134897/ozempic-kan-ifoelge-nyt-studie-forebygge-kronisk-nyresygdom/?utm_campaign=FINANS Briefing&utm_content=2024-05-27&utm_medium=email&utm_source=finans
-
-
-
Sydbank: Amerikansk nej til Novos nye insulin er ikke verdens undergang https://proinvestor.com/investornyt/1164781/sydbank-amerikansk-nej-til-novos-nye-insulin-er-ikke-verdens-undergang
-
Novo Nordisk: Considerable Growth Beyond Ozempic https://seekingalpha.com/article/4695766-novo-nordisk-stock-considerable-growth-beyond-ozempic?mailingid=35514672&messageid=must_reads&serial=35514672.2170798&utm_campaign=email_mr%3Aevergreen_premium_eligible%2B2024-05-27&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads_free_eligible
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind